Pieris has established a proprietary portfolio of unique product opportunities in anemia, asthma and oncology. Based on the promise of our unique therapeutic approach in immuno-oncology, we intend to make this a core franchise of the Company.

Pieris also maintains multi-program R&D collaborations with Servier, Roche, Daiichi Sankyo and the Sanofi Group to bring its proprietary Anticalin technology to patients in a variety of indications. To maximize the value of our pipeline, we are continuing to explore new partnerships to support the development and commercialization of the technology.

Immuno-Oncology

View Programs »
Candidate Targets Indication Partner Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
PRS-343 4-1BB/HER2 Bispecific Immuno-Oncology Worldwide
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started
PRS-342 4-1BB/GPC3 Bispecific Immuno-Oncology Worldwide
Discovery Phase completed
Pre-Clinical Phase in progress
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started
PRS-300s n.d. Immuno-Oncology Worldwide
Discovery Phase in progress
Pre-Clinical Phase not started
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started
PRS-332 PD-1/n.d. Bispecific Immuno-Oncology U.S.
Discovery Phase completed
Pre-Clinical Phase in progress
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started
Servier 4 Programs n.d./n.d. Bispecific Immuno-Oncology U.S. / Milestones & Royalties
Discovery Phase completed
Pre-Clinical Phase not started
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started
Roche n.d. Immuno-Oncology Milestones & Royalties
Discovery Phase in progress
Pre-Clinical Phase not started
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started

Respiratory, Anemia and Other Disease Areas

View Programs »
Candidate Targets Indication Partner Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
PRS-080 Hepcidin Anemia Major Markets Ex-Japan
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase completed
Phase 1 completed
Phase 2 in progress
PRS-060 IL4Ra Asthma Worldwide
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started
DS-9001 PCSK9 Dyslipidemia Milestones & Royalties
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase completed
Phase 1 in progress
Phase 2 not started
Daiichi Sankyo n.d. n.d. Milestones & Royalties
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started
Sanofi P. aeruginosa Infectious Disease Milestones & Royalties
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started
PRS-110 cMet Oncology Major Markets
Discovery Phase completed
Pre-Clinical Phase in progress
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started